What Pretzel Therapeutics does

Pretzel Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule and antisense oligonucleotide therapies that target mitochondrial dysfunction to treat rare genetic diseases, metabolic conditions, and neurodegenerative disorders. Founded in 2022 and headquartered in Waltham, Massachusetts, with research facilities in Mölndal, Sweden (GoCo Health Innovation City), the company operates three proprietary platform technologies: (1) genome correction therapeutics that reduce mutated mitochondrial DNA and increase healthy mtDNA levels, (2) genome expression modulation using small molecules acting on enzymes involved in mtDNA replication, transcription, and translation, and (3) mitochondrial quality control via small molecules that modulate mitochondria's built-in quality control machinery.

The lead asset PX578 is a first-in-class small molecule activator of mitochondrial DNA polymerase POLG, currently in Phase 1 clinical development for POLG disease and broader mitochondrial DNA depletion syndromes, with demonstrated activity across all POLG mutations tested including the four most common mutations covering approximately 70% of patients. The pipeline also includes a SAMHD1 program (preclinical) and a POLRMT antisense oligonucleotide program (late preclinical) targeting obesity and metabolic disease, supported by a Nature Metabolism publication. Scientific founders include Nobel Laureate Sir John Walker, Claes Gustafsson, Maria Falkenberg, Michal Minczuk, and Nils-Göran Larsson—world-leading academic experts in mitochondrial biology.

The company is pre-revenue with no approved products and no disclosed pricing. Its business model is to advance therapies through clinical trials (Phase 1 ongoing in Australia/U.S., Phase 2 planned for H2 2026) toward regulatory approval with the FDA, EMA, and other health authorities, and to commercialize approved therapeutics through standard pharmaceutical channels—including specialty pharmacies for rare disease indications and broader channels for metabolic and neurodegenerative conditions. Capital has been raised through a $72.5 million Series A led by ARCH Venture Partners and Mubadala Capital (September 2022), a follow-on investment from The Mito Fund (July 2025), and a Parkinson's UK grant (April 2025). The company employs 11–50 staff, executed an acquisition of ROME Therapeutics in January 2026, and pursues its GTM through clinical development partnerships, academic collaborations, and regulatory engagement.

Name

Pretzel Therapeutics

Legal name

Pretzel Therapeutics, Inc.

Website

https://pretzeltx.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Pretzel Therapeutics is a clinical-stage biotechnology company developing first-in-class therapies that target mitochondrial dysfunction to treat rare genetic mitochondrial diseases, metabolic conditions including obesity, and neurodegenerative disorders.

Ownership category

akta.pro rank

Product category

Mitochondrial Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)

akta.pro secondary industry

Enzyme Replacement & Metabolic Disorder Therapies (HLAIAIAB)

Keywords

• Mitochondrial therapeutics
• Rare disease treatments
• Small molecule drugs
• Clinical-stage biotechnology
• Mitochondrial DNA depletion

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Drug Development and Commercialization: Pretzel Therapeutics is a pre-revenue clinical-stage biotechnology company. The company is developing a pipeline of novel mitochondrial therapies with its lead program PX578 in Phase 1 clinical development for POLG disorders and mitochondrial DNA depletion syndromes. The company plans to commercialize its therapies upon regulatory approval. Revenue will be generated through sales of approved therapeutics for rare diseases and common conditions such as metabolic diseases and neurodegenerative disorders.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Pretzel Therapeutics is a clinical-stage biotechnology company developing a pipeline of first-in-class therapies that target mitochondrial dysfunction. The company leverages three proprietary platform technologies — genome correction therapeutics (gene-editing tools to reduce mutated mitochondrial DNA and increase healthy mtDNA), genome expression modulation (small molecules acting on enzymes involved in mtDNA replication, transcription, and translation), and mitochondrial quality control (small molecules modulating mitochondria's built-in quality control system) — to address rare mitochondrial DNA depletion syndromes, neurodegenerative diseases, and metabolic conditions including obesity.

Product overview

Pretzel Therapeutics is developing a broad pipeline of first-in-class treatments addressing novel targets within mitochondria for rare and common diseases. The company operates two main therapeutic franchises: (1) the Bioenergetics Restoration Franchise led by PX578 (a first-in-class POLG activator in Phase 1) and the SAMHD1 program (preclinical), targeting rare mitochondrial DNA depletion syndromes and neurodegenerative diseases; and (2) the Bioenergetics Modulation Franchise led by the POLRMT program (late preclinical), targeting metabolic conditions including obesity. The pipeline spans neurological, muscular atrophies, metabolic and rare disease indications.

Differentiator

Problem solved

Functional benefit

Products and services

• PX578 PX578 is a first-in-class small molecule activator of mitochondrial DNA polymerase POLG designed to increase mtDNA levels and address the underlying cause of mitochondrial DNA depletion syndromes (MDDS), including POLG disease. It has demonstrated activity across all tested POLG mutations, including the four most common mutations found in approximately 70% of POLG patients, and is currently in Phase 1 clinical development for rare mtDNA depletion syndromes and broader degenerative diseases.
• POLRMT Program The POLRMT program is the lead in the energetics modulation franchise, targeting mitochondrial RNA polymerase (POLRMT) for the treatment of metabolic conditions including obesity. The program uses a liver-directed antisense oligonucleotide approach to knock down POLRMT, resulting in increased energy expenditure and improved body composition. Currently in late preclinical development.
• SAMHD1 Program The SAMHD1 program is the second target in the energetics restoration franchise. SAMHD1 is a key driver of mtDNA levels and represents a potentially complementary mechanistic approach to POLG activation. Currently in preclinical development.

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and major.

• Karolinska InstitutetcoreStrategic or Co-development Partner · 4 November 2025Co-founder Nils-Göran Larsson is Professor of Mitochondrial Genetics at the Department of Medical Biochemistry and Biophysics at Karolinska Institutet. Research by Larsson published in Nature Metabolism on POLRMT inhibition and metabolic effects forms the scientific basis for the company's POLRMT program.
• University of GothenburgcoreStrategic or Co-development Partner · 9 April 2025Pretzel's scientific co-founders from the University of Gothenburg collaborated on the Nature publication describing the discovery of novel activators that restore function to mutant mitochondrial DNA polymerases. The research was conducted in collaboration with Pretzel co-founders Claes Gustafsson and Maria Falkenberg from the University of Gothenburg.
• Parkinson's UKmajorStrategic or Co-development Partner · 3 April 2025Parkinson's UK awarded grant funding to support evaluation of Pretzel's POLG activation mechanism in Parkinson's disease models in collaboration with Dr. Roberta Filograna's lab at the Karolinska Institute, Stockholm, Sweden. This represents a strategic research collaboration to explore POLG activation for Parkinson's disease treatment.
• MRC Mitochondrial Biology Unit, University of CambridgecoreStrategic or Co-development Partner · 1 January 2024Pretzel co-founders Michal Minczuk and Sir John Walker are associated with the MRC Mitochondrial Biology Unit at University of Cambridge. Sir John Walker, a Nobel Laureate, serves on the Scientific Advisory Board. The MRC Mitochondrial Biology Unit research underlies the company's platform technologies.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Reneo Pharmaceuticals: Clinical-stage biotech developing therapies for rare genetic mitochondrial diseases, with lead asset mavodelpar (REN001) advancing in clinical trials. Closely aligned business model and patient population focus.
• Stealth BioTherapeutics: Clinical-stage biotech developing mitochondria-targeted therapies for rare diseases including mitochondrial myopathies. Most direct competitor in the mitochondrial disease therapeutic space, with elamipretide (SS-31) advancing in clinical trials.
• Khondrion: Clinical-stage pharmaceutical company developing small molecules targeting mitochondrial dysfunction for primary mitochondrial diseases and other disorders. Directly comparable in mission and target indications (mitochondrial diseases).
• Abliva (formerly NeuroVive Pharmaceutical): Swedish clinical-stage biotech developing mitochondrial medicine for primary mitochondrial diseases, with KL1333 in late-stage development. Comparable both by indication focus and by Nordic/European research footprint similar to Pretzel's Swedish R&D base.

Emerging players

• Minovia Therapeutics: Clinical-stage company developing mitochondrial cell therapies (autologous mitochondrial transplantation) for mitochondrial diseases. Partial overlap — also targets mitochondrial dysfunction but with a distinct cell-therapy modality.
• Poxel: Clinical-stage French biotech developing drugs for metabolic disorders, including TWYMEEG (imeglimin) for type 2 diabetes, with mitochondrial mechanism of action. Comparable on the metabolic franchise side of Pretzel's pipeline.
• Cyclerion Therapeutics: Clinical-stage biotech pursuing rare diseases including mitochondrial and CNS indications. Has overlapping therapeutic interest and comparable small-molecule development approach, though currently focused on different targets.
• Casma Therapeutics: Biotech developing autophagy- and lysosome-based therapies for rare diseases. Senior Research Advisor Jeff Saunders serves both companies. Adjacent in the broader cellular quality control and rare disease therapeutic space.

Broad incumbents

• Astellas Pharma (Mitobridge): Japanese big pharma that acquired Mitobridge to build a mitochondrial disease franchise. Broader portfolio but overlapping therapeutic area and substantially greater resources for development and commercialization.
• Reata Pharmaceuticals (Biogen): Reata developed Skyclarys (omaveloxolone) for Friedreich's ataxia, a mitochondrial disease therapeutic, and was acquired by Biogen. A relevant reference point for a successful rare mitochondrial disease commercial story at scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/pretzeltx

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds3 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pretzel Therapeutics